Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 13/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 11/20 | 1.00 |
| ▸ | BACE1 | P56817 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629007 | 0.87 | SCN2A (0.77) | SCN2ASCN5ABACE1L3MBTL1HTR7 | |
| SCHEMBL4629295 | 0.85 | SCN2A (0.74) | SCN2ASCN5ABACE1LMNAHTR7 | |
| SCHEMBL4628365 | 0.82 | SCN2A (1.00) | SCN2ASCN5AL3MBTL1 | |
| SCHEMBL6702037 | 0.82 | SCN2A (0.69) | SCN2ASCN5ABACE1HTR7 | |
| SCHEMBL4629286 | 0.79 | SCN2A (1.00) | SCN2ASCN5A | |
| SCHEMBL4628397 | 0.75 | SCN2A (0.60) | SCN2ASCN5ALMNAPKML3MBTL1 | |
| SCHEMBL4629436 | 0.72 | SCN2A (1.00) | SCN2ASCN5A | |
| SCHEMBL4629468 | 0.72 | SCN2A (0.72) | SCN2ASCN5ABACE1L3MBTL1 | |
| SCHEMBL4628984 | 0.71 | MEN1 (0.80) | SCN2ASCN5AL3MBTL1 | |
| SCHEMBL17583642 | 0.70 | L3MBTL1 (0.61) | SCN2ASCN5ALMNAPKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN2A 1613/4885SCN5A 1196/4885BACE1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.